Metformin discontinue — Competitive Intelligence Brief

Metformin discontinue (Metformin discontinue) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

marketed Biguanide AMP-activated protein kinase (AMPK); hepatic glucose production Diabetes Small molecule

Target snapshot

Metformin discontinue (Metformin discontinue) — University of Texas Southwestern Medical Center. This entry represents a discontinuation of metformin therapy rather than a new drug entity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin discontinue TARGET	Metformin discontinue	University of Texas Southwestern Medical Center	marketed	Biguanide	AMP-activated protein kinase (AMPK); hepatic glucose production
GLIMEPIRIDE + METFORMIN	GLIMEPIRIDE + METFORMIN	Sanofi	marketed	Sulfonylurea + biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial respiratory chain complex I
Mandated back ground therapy	Mandated back ground therapy	Sanofi	marketed	biguanide
Metformin + Clomiphene	Metformin + Clomiphene	University of Auckland, New Zealand	marketed	Combination therapy: biguanide + selective estrogen receptor modulator (SERM)	Metformin: AMP-activated protein kinase (AMPK); Clomiphene: estrogen receptor (ER)
Metformin / Placebo treatment for 4 months	Metformin / Placebo treatment for 4 months	Norwegian University of Science and Technology	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
or Metformin HCl alone	or Metformin HCl alone	Bristol-Myers Squibb	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
Linagliptin / Metformin Oral Tablet	Linagliptin / Metformin Oral Tablet	Universidad de Guanajuato	marketed	DPP-4 inhibitor / Biguanide combination	DPP-4 (dipeptidyl peptidase-4) / AMPK pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

1. AstraZeneca · 4 drugs in this class
2. Merck Sharp & Dohme LLC · 3 drugs in this class
3. University of Texas Southwestern Medical Center · 2 drugs in this class
4. Mount Sinai Hospital, Canada · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Eli Lilly and Company · 2 drugs in this class
7. University Magna Graecia · 2 drugs in this class
8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class